News

Everest Medicines Achieves Record Revenue and Growth in 2024

Everest Medicines Achieves Record Revenue and Growth in 2024

Everest Medicines Achieves Remarkable Financial Success

Everest Medicines, a groundbreaking biopharmaceutical company focused on innovative healthcare solutions, has reported remarkable financial results for the year ending December 31, 2024. With a robust revenue growth of 461%, the company stands out in the pharmaceutical industry, showcasing its resilience and dynamic approach in addressing critical medical needs.

Overview of Financial Performance

Rogers Yongqing Luo, CEO of Everest Medicines, stated, "In 2024, we executed our 'Dual-Engine' strategy effectively, which blends in-house discovery with global partnerships. This balanced approach enabled us to deliver outstanding results, with total revenue reaching RMB706.7 million, surpassing our initial guidance of RMB700 million. Furthermore, we narrowed our non-IFRS net loss by 25%, while our gross margin improved to an impressive 83%."

Commercial Achievements in 2024

Launch of NEFECON®

A significant highlight for Everest Medicines was the successful launch of NEFECON® in mainland China in May 2024, marking a new chapter in treating IgA nephropathy (IgAN). The product generated revenue of RMB353.4 million, reflecting a phenomenal growth of 1,581% year-over-year. Additionally, NEFECON® was included in China's National Reimbursement Drug List (NRDL), ensuring wider access for patients and addressing an essential medical need.

Expansion of XERAVA®

Everest Medicines also reported strong growth with XERAVA® (eravacycline), achieving RMB352.8 million in revenue—an increase of 256% from the previous year. This growth was propelled by the product's unique clinical profile, boosted by rising demand across various markets.

Strategic Pipeline Developments

The company's commitment to innovation is evident as it continues to advance its product pipeline. In 2024, Everest's autoimmune portfolio saw substantial progress with VELSIPITY® (etrasimod), receiving regulatory approvals in various regions, including Macau and Singapore. This product is poised for significant commercial launch and has completed the first patient dosing in its ongoing studies.

Innovations in mRNA Development

Everest Medicines is also making strides in mRNA technology, emphasizing the development of personalized therapeutic approaches. The company recently initiated the first in-human trial of EVM16, its personalized mRNA cancer vaccine, demonstrating its commitment to cutting-edge treatments and showcasing its robust R&D capabilities.

Looking Ahead

As 2025 unfolds, Everest Medicines aims to continue capitalizing on its successful brand momentum. A primary focus will be accelerating the sales of NEFECON®, leveraging its unique position as the only approved IgAN therapy in China. The strategy also includes exploring international partnerships for EVER001, a promising next-generation BTK inhibitor, to maximize its commercial potential outside of the Chinese market.

Emphasis on R&D and Future Growth

With a firm commitment to R&D, Everest Medicines plans to maintain significant investments across its various product pipelines. Upcoming initiatives include submitting NDA applications for VELSIPITY® in multiple regions and seeking further regulatory approvals to enhance treatment accessibility for patients.

About Everest Medicines

Everest Medicines is dedicated to pioneering transformative biopharmaceutical products that meet the needs of patients in Asia. With a diverse portfolio spanning renal diseases, infectious diseases, and autoimmune disorders, the company is positioned to lead advancements in innovative therapies, aiming for a brighter health future for diverse patient populations.

Frequently Asked Questions

What were Everest Medicines' total revenues for 2024?

Everest Medicines reported total revenues of RMB706.7 million for the year 2024, a significant growth of 461% compared to the previous year.

What were the key products contributing to revenue in 2024?

The notable contributors to the revenue included NEFECON®, generating RMB353.4 million, and XERAVA®, which produced revenue of RMB352.8 million.

How is Everest Medicines expanding its product reach?

Everest is expanding its product reach by actively pursuing regulatory approvals in multiple regions and enhancing its commercial capabilities through partnerships and direct market engagement.

What is the significance of NEFECON® for Everest Medicines?

NEFECON® represents a major advancement in treating IgA nephropathy, being the only approved therapy in its category in China and included in the NRDL for greater patient accessibility.

What is Everest Medicines' outlook for 2025?

For 2025, Everest Medicines aims to enhance sales of NEFECON®, advance its R&D initiatives, and expand the availability of its therapies across Asia.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MemorialCare Expands Cutting-Edge GERD Treatment Options

Updated Category News Views 0

Shifting the GERD Treatment Paradigm While everyone's talking about breakthrough technologies like AI and blockchain in medicine, MemorialCare seems to have quietly flipped the script on treating gastroesophageal reflux disease (GERD). They're sidestepping conventional maneuvers by embracing two procedures known as transoral incisionless fundoplication (TIF) and its...

Continue Reading
Military Medical Minds to Converge at MTEC Event in 2027

Updated Category News Views 57

Ever wonder where the cutting edge of military medicine takes shape? On February 16-17, 2027, Washington, DC becomes the epicenter for just that, as the Medical Technology Enterprise Consortium (MTEC) rolls out its 11th Annual Membership Meeting. A gathering of who's who in the world of military medical innovation, this event is like a high-stakes cocktail of science,...

Continue Reading
LG Energy Solution's Q3 2026: Power Moves in ESS Expansion

Updated Category News Views 0

LG's Strategic Battery Play You know it's serious when a company pushes into new territories with gusto. LG Energy Solution isn’t tiptoeing with their recent financials—Q3 2026 showed 'em raking in KRW 9.6 trillion in revenue. That's a mighty 27.6% uptick from the previous quarter, no small potatoes by any stretch, especially when their operating profit stands solid...

Continue Reading
PSEG Q3 2026: Mixed Earnings Amidst Storms and Stability

Updated Category News Views 93

Decoding PSEG's Q3 2026 Performance A company's quarterly performance can feel a bit like checking the weather: you are never quite sure what's coming your way. For PSEG's (NYSE: PEG) third quarter of 2026, the skies were full of mixed signals. Just looking at the headline earnings number, $0.76 per share in net income, there's a drop from last year's $1.24. That’s a...

Continue Reading
Grupo Bimbo Climbs Rankings as Top Global Employer

Updated Category News Views 73

Grupo Bimbo’s Big Leap on the Global Stage Cranking out a solid rise in reputation, Grupo Bimbo has jumped up 107 positions to seize the 444th spot in the 2026 Forbes 'World's Best Employers' list. This isn't just a one-off headline-grabber; it's a testament to the serious work going on behind the scenes at this baking giant. Clawing its way higher from rank 551 in the...

Continue Reading
Latitude Expands Food Allergy Care to Long Island

Updated Category News Views 139

New Clinic Brings Specialized Care to Long Island Listen, when it comes to healthcare, especially something as life-altering as food allergies, you're not just looking for any run-of-the-mill clinic. You're looking for the right place with the right people who get it. And folks in Long Island are getting something worth celebrating—a new clinic from Latitude Food...

Continue Reading
Chicken Salad Chick's Utah Expansion: The Next Course

Updated Category News Views 109

A New Serving in Spanish Fork Chicken Salad Chick is taking another bite out of the Utah market with the opening of its second location in Spanish Fork. On deck for a November 17 debut, this fast-casual chain is serving up not just chicken salad, but a hefty dose of Southern hospitality and promotional giveaways to boot. The big hook? Be among the first 100 patrons and...

Continue Reading
Ericsson Executes Aggressive $54M Share Buyback

Updated Category News Views 62

Digging Into Ericsson's Latest Buyback Getting straight to brass tacks, the recent maneuver by Ericsson (SE0000108656)—snapping back 500,000 shares from October 26 to October 30, 2026—raised more than a few eyebrows in the financial alleys. Shelling out SEK 54.46 million in less than a week is no small potatoes, but it’s all part of a grander financial ballet...

Continue Reading
Spire Missouri's Rate Hike: Safety or Financial Squeeze?

Updated Category News Views 99

A Rate Hike Tied to Safety or a Customer Burden? Listen up, what we've got here is Spire Missouri stamping down with a rate hike to bolster safety and reliability. It's a classic gas provider move, asking the Missouri Public Service Commission to greenlight this hike that’d have bills going up—$10 in the west, $13 in the east. That's 11% and 15% jumps. Not small...

Continue Reading
PropHub's Big Bet on Composability and Growth

Updated Category News Views 78

PropHub Charts a New Course How do you turn a traditional brokerage and trading landscape upside down? PropHub seems to think it has the answer by taking a modular approach to technology integration. It's not just tinkering at the edges; it's about fundamentally changing how components in trading platforms can be configured to suit a wide range of needs. Sounds like a...

Continue Reading

Top 5 Most Recently Viewed Articles

XRP Healthcare Unveils Revolutionary HIPAA-Compliant App in Africa

Updated Category News Views 191

XRP Healthcare's Groundbreaking Digital Health App XRP Healthcare has made a significant advancement in the healthcare sector with the launch of its flagship XRPH AI App, tailored to meet HIPAA-grade standards. This marks a historic moment as the first digital health application in Africa committed to keeping all personal health information securely encrypted on users'...

Continue Reading
Horatio's Impressive Rise: A Future Leader in CX Services

Updated Category News Views 263

Horatio Achieves a Remarkable Recognition in Business Growth In a significant achievement for the modern outsourcing company, Horatio has been ranked at No. 1,168 on the esteemed Inc. 5000 list for the year 2025. This annual list, published by Inc. Magazine, celebrates the most dynamic and fastest-growing private companies across the United States. Notably, this...

Continue Reading
Old Republic Launches New Cyber Underwriting Subsidiary

Updated Category News Views 154

Old Republic's New Venture into Cyber Insurance Old Republic International Corporation (NYSE: ORI) has unveiled its exciting plans to form a new underwriting subsidiary focused on a growing niche in the insurance market—Cyber and Technology Errors and Omission (E&O) insurance. The new entity, named Old Republic Cyber, Inc., aims to provide specialized coverage that...

Continue Reading
Syra Health's Recent Contract: Enhancing Medical Management

Updated Category News Views 107

Syra Health Rewards New Contract for Medical Management Syra Health, a leading healthcare technology company, recently announced securing a contract potentially worth $2.1 million with a major insurance provider. This agreement allows Syra Health to provide registered nurses to enhance medical management and support specific health plans. Understanding the Contract's...

Continue Reading
Dollar and Yields Rise Amid Inflation Impact on Small Caps

Updated Category News Views 83

Understanding Recent Inflation Trends In a recent analysis, U.S. inflation for August has decreased to its lowest annual rate since early 2021, creating an intriguing financial situation. The current inflation rate is at 2.5%, down from 2.9% in July, and slightly below the anticipated 2.6%. Yet, there’s more to this story than just reassuring statistics. If we delve...

Continue Reading